Integrated strategies for identifying leads that target the ns3 helicase of the hepatitis C virus

Journal of Medicinal Chemistry

Volumn 57, Issue 5, 2014, Pages 2074-2090

  LaPlante, Steven R ^a   Padyana, Anil K ^b   Abeywardane, Asitha ^b   Bonneau, Pierre ^a   Cartier, Mireille ^a   Coulombe, René ^a   Jakalian, Araz ^a   Wildeson Jones, Jessi ^c   Li, Xiang ^b   Liang, Shuang ^b   McKercher, Ginette ^a   White, Peter ^a   Zhang, Qiang ^b   Taylor, Steven J ^b  

^a BOEHRINGER INGELHEIM CANADA LTD   (Canada)

^b Department of Medicinal Chemistry ^*  (United States)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HELICASE; INDOLE DERIVATIVE; NONSTRUCTURAL PROTEIN 3;

ARTICLE; BINDING KINETICS; BIOINFORMATICS; CIRCULAR DICHROISM; COMPUTER MODEL; CONTROLLED STUDY; HEPATITIS C VIRUS; IN VITRO STUDY; ISOTHERMAL TITRATION CALORIMETRY; LIGAND BINDING; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; VIRUS INHIBITION; X RAY CRYSTALLOGRAPHY;

ANTIVIRAL AGENTS; ENZYME INHIBITORS; HEPACIVIRUS; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; RNA HELICASES; SERINE ENDOPEPTIDASES; STRUCTURE-ACTIVITY RELATIONSHIP; SURFACE PLASMON RESONANCE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84896268369     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401432c     Document Type: Article

References (45)

1. Lavanchy, D. The global burden of hepatitis C Liver Int. 2009, 29, 74-81
2. Ryan, K. J.; Ray, C. G., Eds. Sherris Medical Microbiology: An Introduction to Infectious Diseases, 4 th ed.; McGraw Hill: New York, 2005; pp 551-552.
3. Choo, Q. L.; Kuo, G.; Weiner, A. J.; Overby, L. R.; Bradley, D. W.; Houghton, M. Isolation of a cDNA Clone Derived from a Blood-borne non-A, non-B Viral Hepatitis Genome Science 1989, 244, 359-362
4. Ghany, M. G.; Strader, D. B.; Thomas, D. L.; Seeff, L. B. American Association for the Study of Liver Diseases. Diagnosis, Management, and Treatment of hepatitis C: An Update Hepatology 2009, 49, 1335-1374
5. Pearlman, B. L. Protease Inhibitors for the Treatment of Chronic Hepatitis C Genotype-1 Infection: The New Standard of Care Lancet Infect. Dis. 2012, 12, 717-728
6. See, for example, LaPlante, S. R.; Nar, H.; Lemke, C.; Jakalian, A.; Aubry, N.; Kawai, S. Ligand Bioactive Conformation Plays a Critical Role in the Design of Drugs That Target the Hepatitis C Virus NS3 Protease J. Med. Chem. 2014, HCV Therapies Special Issue 10.1021/jm401338c
7. Sarrazin, C.; Zeuzem, S. Resistance to Direct Antiviral Agents in Patients with Hepatitis C Virus Infection Gastroenterology 2010, 138, 447-462
8. Welsch, C.; Zeuzem, S. Will Interferon-Free Regimens Prevail? Gastroenterology 2012, 142, 1351-1355
9. Moradpour, D.; Penin, F.; Rice, C. M. Replication of Hepatitis C Virus Nat. Rev. Microbiol. 2007, 5, 453-463
10. Sofia, M. J.; Chang, W.; Furman, P. A.; Mosley, R. T.; Ross, B. S. Nucleoside, Nucleotide, and Non-nucleoside Inhibitors of Hepatitis C Virus NS5B RNA-Dependent RNA-Polymerase J. Med. Chem. 2012, 55, 2481-2531
11. See, for example, LaPlante, S. R.; Bos, M.; Brochu, C.; Chabot, C.; Coulombe, R.; Gillard, J. R.; Jakalian, A.; Poirier, M.; Rancourt, J.; Stammers, T.; Thavonekham, B.; Beaulieu, P. L.; Kukolj, G.; Tsantrizos, Y. S. Conformation-Based Restrictions and Scaffold Replacements in the Design of HCV Polymerase Inhibitors: Discovery of Deleobuvir (BI 207127) J. Med. Chem. 2014, HCV Therapies Special Issue 10.1021/jm4011862
12. Thibeault, D.; Maurice, R.; Pilote, L.; Lamarre, D.; Pause, A. In Vitro Characterization of a Purified NS2/3 Protease Variant of Hepatitis C Virus J. Biol. Chem. 2001, 276, 46678-46684
13. Pallaoro, M.; Lahm, A.; Biasiol, G.; Brunetti, M.; Nardella, C.; Orsatti, L.; Bonelli, F.; Orru, S.; Narjes, F.; Steinkuhler, C. Characterization of the Hepatitis C Virus NS2/3 processing Reaction by Using a Purified Precursor Protein J. Virol. 2001, 75, 9939-9946
14. Li, K.; Frankowski, K. J.; Belon, C. A.; Neuenswander, B.; Ndjomou, J.; Hanson, A. M.; Shanahan, M. A.; Schoenen, F. J.; Blagg, B. S.; Aube, J.; Frick, D. N. Optimization of Potent Hepatitis C Virus NS3 Helicase Inhibitors Isolated from the Yellow Dyes Thioflavine S and Primuline J. Med. Chem. 2012, 55, 3319-3330
15. Mukherjee, S.; Hanson, A. M.; Shadrick, W. R.; Ndjomou, J.; Sweeney, N. L.; Hernandez, J. J.; Bartczak, D.; Li, K.; Frankowski, K. J.; Heck, J. A.; Arnold, L. A.; Schoenen, F. J.; Frick, D. N. Identification and Analysis of Hepatitis C Virus NS3 Helicase Inhibitors Using Nucleic Acid Binding Assays Nucleic Acids Res. 2012, 40, 8607-8621
16. Pyle, A. M. RNA Helicases and Remodeling Proteins Curr. Opin. Chem. Biol. 2011, 15, 636-664
17. Liu, D.; Wyss, D. F. Backbone 1H, 15N and 13C Resonance Assignments of the NTPase Subdomain of the Hepatitis C Virus NS3 RNA Helicase J. Biomol. NMR 2001, 19, 283-284
18. Gesell, J. J.; McCoy, M. A.; Senoir, M. M.; Wang, Y. S.; Wyss, D. F. NMR-Based Screening Applied to Drug Discovery Targets. In Modern Magnetic Resonance; Webb, G.A., Ed.; Springer: Dordrecht, the Netherlands, 2006; pp 1401-1410.
19. Boguszewska-Chachulska, A. M.; Krawczyk, M.; Najda, A.; Kopańska, K.; Stankiewicz-Drogoń, A.; Zagórski-Ostoja, W.; Bretner, M. Searching for a New Anti-HCV Therapy: Synthesis and Properties of Tropolone Derivatives Biochem. Biophys. Res. Commun. 2006, 341, 641-647
20. Borowski, P.; Schalinski, S.; Schmitz, H. Nucleotide Triphosphatase/ Helicase of Hepatitis C Virus as a Target for Antiviral Therapy Antiviral Res. 2002, 55, 397-412
21. During the course of fragment expansion, a patent application was issued with overlapping chemical matter. See: Beigelman, B.; Buckman, B.; Wang, G.; Matulic-Adamic, J.; Stoycheva, A. D.; Andrews, S. W.; Misialek, S. M.l; Rajagopalan, P. T.; Fryer, A. M.; Gunawardana, I.; Haas, J.; Huang, L.; Maduru, M. R.; Zhang, G.; Kossen, K.; Serebry, V. Novel Inhibitors of Hepatitis C Virus Replication, WO 2008/100867, 2008.
22. Cheng, W.; Arunajadai, S. G.; Moffitt, J. R.; Tinoco, I., Jr.; Bustamante, C. Single-Base Pair Unwinding and Asynchronous RNA Release by the Hepatitis C Virus NS3 Helicase Science 2011, 333, 1746-1749
23. Kim, J. L.; Morgenstern, K. A.; Griffith, J. P.; Dwyer, M. D.; Thomson, J. A.; Murcko, M. A.; Lin, C.; Caron, P. R. Hepatitis C Virus NS3 RNA Helicase Domain with a Bound Oligonucleotide: The Crystal Structure Provides Insights into the Mode of Unwinding Structure 1998, 6, 89-100
24. Brady, G. P.; Stouten, P. F. W. Fast prediction and visualization of protein binding pockets with PASS J. Comput.-Aided Mol. Des. 2000, 14 (4) 383-401
25. Albert, J. S.; Blomberg, N.; Breeze, A. L.; Brown, A. J.; Burrows, J. N.; Edwards, P. D.; Folmer, R. H.; Geschwindner, S.; Griffen, E. J.; Kenny, P. W.; Nowak, T.; Olsson, L. L.; Sanganee, H.; Shapiro, A. B. An Integrated Approach to Fragment-Based Lead Generation: Philosophy, Strategy and Case Studies from AstraZeneca's Drug Discovery Programmes Curr. Top. Med. Chem. 2007, 7, 1600-1629
26. Zartler, E. R.; Shapiro, M. J. Fragment-based Drug Discovery: A Practical Approach; John Wiley & Sons: Chichester, U.K., 2008.
27. Folkers, G.; Jahnke, W.; Erlanson, D. A.; Mannhold, R.; Kubinyi, H. Fragment-based Approaches in Drug Discovery; Methods and Principles in Medicinal Chemistry; Wiley-VCH: Weinheim, Germany, 2006, ISBN 3-527-31291-9.
28. Shuker, S.B.; Hajduk, P.J.; Meadows, R.P.; Fesik, S.W. Discovering High-Affinity Ligands for Proteins: SAR by NMR Science 1996, 274, 1531-1534
29. LaPlante, S. R.; Carson, R.; Gillard, J.; Aubry, N.; Coulombe, R.; Bordeleau, S.; Bonneau, P.; Little, M.; O'Meara, J.; Beaulieu, P. L. Compound Aggregation in Drug Discovery: Implementing a Practical NMR Assay for Medicinal Chemists J. Med. Chem. 2013, 56, 5142-5150
30. LaPlante, S. R.; Aubry, N.; Bolger, G.; Bonneau, P.; Carson, R.; Coulombe, R.; Sturino, C.; Beaulieu, P. L. Monitoring Drug Self-Aggregation and Potential for Promiscuity in Off-target In vitro Pharmacology Screens by a Practical NMR Strategy J. Med. Chem. 2013, 56, 7073-7083
31. LaPlante, S. R.; Aubry, N.; Bonneau, P. R.; Kukolj, G.; Lamarre, D.; Lefebvre, S.; Li, H.; Llinas-Brunet, M.; Plouffe, C.; Cameron, D. R. Line-broadening and Transferred NOESY as a Medicinal Chemistry Tool for Studying Inhibitors of the Hepatitis C Virus NS3 Protease Domain Bioorg. Med. Chem. Lett. 2000, 10 (20) 2271-2274
32. Zhang, M. Q.; Wilkinson, B. Drug discovery beyond the 'rule-of-five' Curr. Opin. Biotechnol. 2007, 18, 478-488
33. Freire, E. Do enthalpy and entropy distinguish first in class from best in class? Drug Discovery Today 2008, 13, 869-874
34. Woody, R. W.; Dunker, A. K. Aromatic and Cystine Side-Chain Circular Dichroism in Proteins. In Circular Dichroism and the Conformational Analysis of Biomolecules; Fasman, G. D., Ed.; Plenum Press: New York, 1996; pp 109-158.
35. Thibeault, D.; Bousquet, C.; Gingras, R.; Lagacé, L.; Maurice, R.; White, P. W.; Lamarre, D. Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061 J. Virol. 2004, 78, 7352-7359
36. Thibeault, D.; Massariol, M. J.; Zhao, S.; Welchner, E.; Goudreau, N.; Gingras, R.; Llinàs-Brunet, M.; White, P. W. Use of the fused NS4A peptide-NS3 protease domain to study the importance of the helicase domain for protease inhibitor binding to hepatitis C virus NS3-NS4A Biochemistry 2009, 48, 744-753
37. Yao, N.; Hesson, T.; Cable, M.; Hong, Z.; Kwong, A. D.; Le, H. V.; Weber, P. C. Structure of the hepatitis C virus RNA helicase domain Nat. Struct. Biol. 1997, 4, 463-467
38. Zhang, S.; Grosse, F. Molecular characterization of nuclear DNA helicase II (RNA helicase A) Methods Mol. Biol. 2010, 587, 291-302
39. Massariol, M. J.; Zhao, S.; Marquis, M.; Thibeault, D.; White, P. W. Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3-NS4A proteins Biochem. Biophys. Res. Commun. 2010, 391, 692-697
40. Beran, R. K.; Lindenbach, B. D.; Pyle, A. M. The NS4A protein of hepatitis C virus promotes RNA-coupled ATP hydrolysis by the NS3 helicase J. Virol. 2009, 83, 3268-3275
41. Ding, S. C.; Kohlway, A. S.; Pyle, A. M. Unmasking the active helicase conformation of nonstructural protein 3 from hepatitis C virus J. Virol. 2011, 85, 4343-4353
42. Yao, N.; Reichert, P.; Taremi, S. S.; Prosise, W. W.; Weber, P. C. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase Structure 1999, 7, 1353-1363
43. Appleby, T. C.; Anderson, R.; Fedorova, O.; Pyle, A. M.; Wang, R.; Liu, X.; Brendza, K. M.; Somoza, J. R. Visualizing ATP-dependent RNA translocation by the NS3 helicase from HCV J. Mol. Biol. 2011, 405, 1139-1153
44. Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K. Features and development of Coot Acta Crystallogr. 2010, D66, 486-501
45. Adams, P. D.; Afonine, P. V.; Bunkóczi, G.; Chen, V. B.; Davis, I. W.; Echols, N.; Headd, J. J.; Hung, L.-W.; Kapral, G. J.; Grosse-Kunstleve, R. W.; McCoy, A. J.; Moriarty, N. W.; Oeffner, R.; Read, R. J.; Richardson, D. C.; Richardson, J. S.; Terwilliger, T. C.; Zwart, P. H. PHENIX: A comprehensive Python-based system for macromolecular structure solution Acta Crystallgr. 2010, D66, 213-221